Welcome to our dedicated page for Endonovo Therape news (Ticker: ENDV), a resource for investors and traders seeking the latest updates and insights on Endonovo Therape stock.
Endonovo Therapeutics Inc. (ENDV) is a pioneering biotechnology company developing bioelectronic solutions for regenerative medicine. This news hub provides investors and industry observers with essential updates on the company's innovative platforms, including Immunotronics™ for non-invasive organ therapy and Cytotronics™ for advanced cell manipulation technologies.
Our curated news collection offers immediate access to official press releases, regulatory filings, and clinical development milestones. Track updates across key areas including product development progress, research collaborations, intellectual property developments, and strategic partnerships within the regenerative medicine sector.
This resource serves as your primary source for monitoring ENDV's advancements in bioelectronic therapies designed to address organ failure and tissue degeneration. Regular updates ensure you stay informed about technological breakthroughs and their potential implications for the healthcare market.
Bookmark this page for streamlined access to verified information about Endonovo's scientific innovations and corporate developments. Check back frequently for real-time updates directly from company filings and authorized communications.
Endonovo Therapeutics, Inc. (OTCQB: ENDV) is advancing its clinical development for treating Traumatic Brain Injury (TBI) with its SofPulse® technology. The company is collaborating with prominent researchers and institutions to evaluate SofPulse®'s effectiveness in alleviating TBI symptoms, including headaches and cognitive impairment. The response from the scientific community has been overwhelmingly positive, indicating significant interest in the technology's potential. The global market for CNS therapeutics is projected to grow from $116.2 billion in 2020 to $214.8 billion by 2028, with the TBI market alone expected to reach $4.5 billion by 2026. Endonovo aims to achieve FDA clearance and reimbursement for SofPulse® treatments, positioning itself for substantial growth in the expanding CNS market.
Endonovo Therapeutics, Inc. (ENDV) announces a partnership with former NFL player David Irving as a brand ambassador for its non-opioid pain relief device, SofPulse®. Irving will share his experiences using the device, which employs Pulsed Electro Magnetic Field (PEMF) therapy showing positive effects on chronic pain and joint injuries. Irving, who retired due to health issues caused by concussions, emphasizes the need for non-pharmaceutical solutions for pain management. The partnership aims to advance awareness of SofPulse® among athletes and patients. Endonovo plans to expand research on PEMF therapy, aiming for FDA clearance for treating traumatic brain injury (TBI), post-concussion syndrome (PCS), and other CNS disorders, highlighting the device's potential in the $40.25 billion pain management market.
